MedTrace Logo

Pharmacogenomic Testing to Optimize Antidepressant Drug Therapy

NCT03591224 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 213

Last updated 2020-07-07

No results posted yet for this study

Summary

A randomized controlled trial comparing pharmacogenomic guided versus standard pharmacist care to optimize antidepressant drug therapy. This study evaluates the effectiveness of pharmacists utilizing pharmacogenomic testing in the community pharmacy setting to help patients find the most appropriate drug therapy option(s) and minimize the risk of side effects in collaboration with prescribing physicians.

Conditions

Interventions

OTHER

Pharmacogenomic Testing

pharmacogenomic drug response test provides personalized insights on a patient's predicted response to medications based on metabolism

OTHER

Pharmacist Standard of Care

Pharmacist providing standard of care as per usual practice

Sponsors & Collaborators

  • Green Shield Canada

    collaborator UNKNOWN

  • John Papastergiou Pharmacy Ltd

    lead INDUSTRY

Principal Investigators

  • John Papastergiou, B.Sc.Phm · University of Toronto

  • Wilson Li, B.Sc.Phm · John Papastergiou Pharmacy Ltd

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-04-17
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03591224 on ClinicalTrials.gov